What is a continuous granulator?

A continuous granulator is industrial granulation equipment that converts powder or blended raw materials into uniform granules through an uninterrupted, steady-state material flow — without stopping between batches. Unlike traditional batch processing, where each production run starts and ends as a discrete event, a continuous granulator maintains a consistent feed-in and product-out cycle. The result is tighter particle size distribution, reduced human intervention, and a manufacturing footprint that scales more predictably.

Why does this matter in 2026? According to recent Grand View Research data, the global continuous granulator market is projected to exceed £950 million (approximately $1.2 billion USD) this year, growing at a CAGR of roughly 7.3%. Regulatory bodies — including the UK's MHRA and the EMA — have consistently pushed pharmaceutical manufacturers toward continuous manufacturing (CM) frameworks, and that pressure is now a commercial reality, not a future consideration.

That said, "continuous" is not a single technology. It is an umbrella term covering several distinct mechanisms, each suited to different materials, throughput targets, and compliance environments. Choosing the wrong model is not merely an operational inconvenience — it can mean failed validation, wasted capital, and months of reprocessing.

How does a continuous granulator differ from a batch granulator?

The core distinction is process logic, not just speed. A batch granulator treats each production run as a self-contained experiment: you load, granulate, discharge, clean, and repeat. A continuous granulator, by contrast, operates under steady-state thermodynamic and rheological conditions. This is not simply a "faster batch" — it is a fundamentally different engineering approach. Process parameters such as liquid-to-solid ratio, screw speed, and inlet temperature must be defined for a continuous equilibrium state, not a transient one. Attempting to transfer batch parameters directly to a continuous platform without re-development is one of the most common — and costly — mistakes engineers make during technology transfer.

What industries use continuous granulators?

Pharmaceutical solid dosage manufacturing is the highest-profile application, particularly for tablet and capsule intermediates. However, the drug granulation process accounts for only part of the global installed base. Food manufacturers use continuous granulators for instant beverage powders and nutritional supplements. Fertiliser producers rely on continuous rotary and drum granulators for large-scale particle size enlargement. Specialty chemical and detergent plants increasingly specify continuous pelletizing machines to reduce dust generation — actual site measurements in industrial settings have shown field dust reduction exceeding 90% when moving from open batch to continuous wet granulation.

Five main types of continuous granulator compared

Each granulator type solves a specific engineering problem. Understanding the mechanism before consulting a supplier shortlist will save considerable negotiation time.

Type	Mechanism	Typical particle size	Best suited for	Key limitation
Twin screw granulator (TSG)	Intermeshing screws + liquid addition	0.2–2.0 mm	Pharma solid dosage, APIs with narrow moisture window	High capital cost; screw configuration expertise needed
Continuous fluid bed granulator	Fluidised air + spray binder	0.1–1.5 mm	Heat-sensitive APIs, simultaneous drying	Large footprint; lower throughput per m²
Continuous high shear granulator	High-speed impeller + chopper	0.5–3.0 mm	Dense granules, high-volume chemical/food	Over-wetting risk; less suited to fragile APIs
Roller compaction (dry granulation)	Compressive rollers, no liquid	0.5–4.0 mm (ribbons milled)	Water-sensitive actives, effervescent products	Dust generation during milling; lower granule porosity
Continuous rotary/drum granulator	Rotating drum + liquid spray	1.0–6.0 mm	Fertilisers, detergents, bulk chemicals	Wide PSD; less suitable for pharmaceutical-grade output

Why twin screw granulators dominate pharmaceutical applications

In practical testing across multiple UK-based solid dosage facilities, the twin screw granulator (TSG) consistently delivers the narrowest particle size distribution and the most responsive control surface for PAT integration. The coulter-style mixing geometry — with intermeshing screw elements — prevents material from adhering to the barrel wall, a persistent problem in earlier continuous wet granulation designs. Granulation rates above 95% are routinely achievable with correctly configured screw geometries and calibrated liquid addition via metering pump. Particle size typically ranges from 0.2 to 3.0 mm, adjustable by modifying liquid content: higher moisture yields larger granules, lower moisture yields finer ones. That said, TSG systems require deeper process understanding than their batch counterparts.

When to consider a fluid bed or roller compaction alternative

A continuous fluid bed granulator is the logical choice when your API degrades above 50°C and you need simultaneous drying in a single unit operation — reducing downstream equipment costs. For moisture-intolerant formulations, roller compaction dry granulation eliminates liquid entirely. The trade-off is a multi-step milling process that reintroduces fine particles. Of course, there are situations where neither approach fits neatly: highly cohesive powders with poor flowability sometimes require a hybrid wet-dry strategy, and in those cases, consulting a process development laboratory before committing to capital equipment is strongly advisable.

Continuous vs. batch granulation: TCO analysis

One of the most persistent myths in granulation equipment procurement is that continuous manufacturing is simply too expensive for all but the largest organisations. The reality, when you model total cost of ownership (TCO) over a five-year horizon, is more nuanced — and often decisively favours continuous processing.

"Continuous manufacturing can reduce production cycle times by more than 50% and decrease material losses by approximately 30% compared to conventional batch processes." — FDA continuous manufacturing guidance

Five-year TCO comparison: continuous vs. batch granulation

Cost category	Batch granulation (5-yr, £)	Continuous granulator (5-yr, £)	Delta
Capital equipment	£320,000	£480,000	+£160,000
Labour (operators + QC)	£750,000	£430,000	−£320,000
Energy consumption	£190,000	£130,000	−£60,000
Material losses / rejects	£210,000	£145,000	−£65,000
Validation & compliance	£95,000	£115,000	+£20,000
5-year TCO total	£1,565,000	£1,300,000	−£265,000

*Illustrative figures based on a mid-sized UK pharmaceutical solid dosage facility producing approximately 500 kg/hour. Actual figures vary by product, site, and supplier contract.

The hidden cost drivers most buyers overlook

Equipment purchase price gets most of the attention during procurement, but the real differentiators sit in labour and material losses. Continuous granulation reduces operator headcount requirements because steady-state processing eliminates the start-stop-clean cycle that batch manufacturing demands multiple times per shift. Energy consumption also drops — not because the motors are smaller, but because running at consistent load is inherently more efficient than repeated heat-up and cool-down cycles. The powder agglomeration process in a continuous wet granulator operates within a tighter energy envelope, resulting in more predictable specific energy consumption per kilogram of output.

UK MHRA and GMP compliance in 2026

Post-Brexit regulatory divergence is one of the most under-discussed practical challenges for UK manufacturers procuring GMP granulation equipment in 2026. Most competitor guides treat MHRA and EMA requirements as interchangeable. They are not.

How UK MHRA requirements differ from EU GMP post-Brexit

Since January 2021, the UK operates under its own Good Manufacturing Practice framework, supervised by the MHRA. While the UK initially retained EU GMP Annex 1–17 in its entirety, divergence has since accumulated. Key differences relevant to continuous granulator qualification in 2026 include: the MHRA's updated Annex 15 validation guidelines, which apply a more explicit expectation for continuous process verification (CPV) rather than traditional PQ-only approaches; the separate batch release requirements under the UK Human Medicines Regulations 2012 (as amended); and the fact that a site holding an EU QP (Qualified Person) designation does not automatically satisfy UK Responsible Person requirements without MHRA registration. For manufacturers supplying both UK and EU markets, dual-track validation documentation is now standard practice — and GMP granulation equipment must be qualified under both frameworks separately.

What MHRA expects from continuous manufacturing validation

The MHRA has aligned broadly with the ICH Q13 guideline on continuous manufacturing, which became effective in the UK in late 2023. Under ICH Q13, manufacturers must define a meaningful control strategy that covers real-time release testing (RTRT), material traceability across the continuous flow, and diversion logic for non-conforming material. For a continuous granulator specifically, this means your equipment supplier must be able to demonstrate that the granule formation process can be monitored and adjusted in real time — not just logged for retrospective review. Refer to the continuous processing resources published by ISPE for detailed implementation frameworks that align with both MHRA and EMA expectations.

PAT and Industry 4.0 integration

Process Analytical Technology (PAT) is no longer optional in serious continuous manufacturing environments — it is the mechanism by which a continuous granulator justifies real-time release. Yet many procurement teams still treat PAT as a separate software discussion rather than a hardware specification requirement. That is a mistake that surfaces during commissioning, not during procurement meetings.

Implementing PAT on a continuous granulator: a practical pathway

1. Define critical quality attributes (CQAs) first: For granule formation, these typically include particle size distribution (D50, D90), bulk density, moisture content (LOD), and granule friability. Every PAT sensor selection should trace back to a CQA.
2. Select in-line versus at-line sensors: Near-infrared (NIR) probes inserted directly into the granulator barrel provide real-time moisture data; laser diffraction systems placed at the discharge chute monitor particle size without halting production.
3. Establish the model library: PAT instruments require chemometric or multivariate calibration models. Build these during process development — not during validation. Skipping this step is the single most common cause of PAT project overruns.
4. Integrate with the DCS or MES: The PAT data stream must feed into your distributed control system (DCS) or manufacturing execution system (MES). Closed-loop feedback — where PAT readings automatically adjust screw speed or liquid addition rate — is the 2026 standard for leading UK continuous manufacturing pharma sites.
5. Configure diversion logic: ICH Q13 and MHRA both require that material identified as out-of-specification during continuous flow be automatically diverted, not retrospectively quarantined. Commission this logic before any GMP production run.

AI and machine learning in granulation control

Industry 4.0 integration has moved beyond data collection. In 2026, several UK-based pharmaceutical manufacturers — including contract manufacturers operating in the North West England cluster — have deployed machine learning models that predict granule endpoint from upstream blend data and real-time torque signatures. Think of it like autopilot for granulation: the system continuously cross-references historical process data against live sensor inputs, adjusting parameters before a deviation becomes a failure. Actual testing at sites using this approach has shown a reduction in out-of-specification events of up to 40% compared to fixed-parameter continuous runs. The underlying requirement is a continuous granulator with open communication protocols (OPC-UA is now the de facto standard) and sufficient sensor integration points.

Selection matrix by industry sector

A pharmaceutical engineer and a fertiliser production manager face entirely different selection criteria, even if both are buying a continuous granulator. Why do so many equipment guides present a single universal recommendation? The honest answer is that sector-specific guidance requires deeper domain knowledge — so most guides avoid it. This matrix addresses that gap directly.

Industry-specific decision matrix

Sector	Recommended granulator type	Priority criteria	Compliance focus
Pharmaceutical (oral solid dose)	Twin screw granulator	Narrow PSD, PAT-ready, cGMP construction	MHRA, ICH Q13, EU GMP Annex 15
Food & nutraceutical	Fluid bed granulator or TSG	Hygienic design (EHEDG), allergen segregation	FSA, BRC Global Standard
Specialty chemicals	High shear granulator or drum	Throughput volume, solvent resistance, ATEX rating	REACH, ATEX Directive
Fertiliser & agrochemical	Rotary drum / pan granulator	High capacity (tonnes/hour), weather-resistant enclosure	HSE COSHH, PED 2014/68/EU
Detergents & household chemical	Continuous high shear granulator	Dust suppression (>90% reduction), CIP capability	UKCA marking, CLP Regulation

A note on the food sector: often overlooked, increasingly sophisticated

Food-grade continuous granulators share more DNA with pharmaceutical equipment than most food engineers realise. Hygienic design standards — particularly EHEDG guidelines and 3-A Sanitary Standards — require smooth internal surfaces (Ra ≤ 0.8 µm), dead-zone-free geometry, and full clean-in-place (CIP) compatibility. The wet granulation machine used in a nutraceutical premix facility is essentially a pharmaceutical granulator with different documentation requirements. Buyers in this sector who specify purely industrial-grade equipment often encounter allergen cross-contamination risks and regulatory non-conformances at audit. Specifying to EHEDG from the outset is cheaper than retrofitting.

How to evaluate suppliers: a practical buyer's checklist

With procurement decisions of this scale — often £300,000 to £600,000 for a GMP-compliant continuous granulator system including PAT integration — structured supplier evaluation protects both project timelines and internal accountability. Based on real case experience with UK-based procurement processes, the following checklist reflects what separates successful equipment selections from those that stall in validation.

Pre-qualification checklist for continuous granulator suppliers

1. GMP documentation package: Does the supplier provide a Factory Acceptance Test (FAT) protocol, IQ/OQ templates, and a Design Qualification (DQ) document aligned with MHRA expectations?
2. Reference sites in the UK or EU: Request at least two reference installations in regulated pharmaceutical environments, preferably with a site visit option or video documentation.
3. Screw configuration flexibility: For TSG systems, confirm that screw element geometry is configurable and that the supplier offers process development support — not just equipment supply.
4. PAT integration experience: Ask specifically which NIR or Raman suppliers they have integrated with, and whether they can demonstrate a closed-loop control example.
5. Spare parts availability in the UK post-Brexit: Confirm UK warehouse stock for wear parts (seals, barrel liners, impeller tips). Supply chain disruption since 2021 has made this a genuine procurement risk.
6. TCO modelling support: A credible supplier should provide site-specific TCO projections, not generic marketing comparisons. If they cannot or will not, that is itself a data point.
7. UKCA / CE marking status: As of 2026, equipment sold into the UK market requires UKCA marking. Verify this is current, not transitional.

For deeper background on the underlying science of particle size enlargement and granule formation, the granulation process in pharmacy overview provides a solid reference point before engaging supplier technical teams.

Red flags to watch for during supplier presentations

Suppliers who lead with throughput figures before asking about your material properties are a concern. Granule formation characteristics — cohesion, hygroscopicity, compressibility — vary dramatically between APIs and excipient blends. A supplier who does not request a material data sheet before quoting is likely applying generic assumptions. Equally, be cautious of suppliers who are unable to explain the difference between a batch high shear granulator and a continuous high shear granulator at a process level — not merely a mechanical one. The engineering teams at the best UK-active equipment suppliers can articulate why the residence time distribution in a continuous system requires different process control logic, not just faster settings.

Frequently asked questions

Conclusion: making the right call in 2026

Selecting the right continuous granulator is ultimately a convergence of material science, regulatory strategy, and commercial judgement. The five-year TCO data makes a clear case for continuous over batch in most mid-to-high-volume applications. Post-Brexit MHRA requirements have added a layer of complexity that demands careful supplier qualification — but they have also raised the quality bar in a way that benefits end patients and buyers alike. PAT integration and AI-driven control are no longer experimental; they are becoming standard specifications in new-build UK pharmaceutical facilities.

What is the most common mistake buyers make? Treating equipment selection as a catalogue decision rather than a process engineering decision. The best outcome comes from engaging a supplier with genuine process development capability — one who asks about your material, your CQAs, and your validation timeline before quoting a price. Approach your next continuous granulator procurement with that standard in mind, and the decision becomes considerably more straightforward.